Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 11, 2020

SELL
$1.01 - $3.42 $42,796 - $144,915
-42,373 Closed
0 $0
Q4 2019

Feb 13, 2020

SELL
$0.87 - $2.89 $34,412 - $114,313
-39,555 Reduced 48.28%
42,373 $118,000
Q3 2019

Nov 08, 2019

BUY
$1.34 - $2.4 $109,783 - $196,627
81,928 New
81,928 $125,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $478M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Winton Group LTD Portfolio

Follow Winton Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.